Recently, it has been shown that antibody blockade of either LILRB1 or HLA-class I promotes phagocytosis of solid tumor cells, that genetic ablation of cell surface expression of HLA class I and CD47 augmented ADCP by anti-EpCAM or anti-EGFR antibodies and that MHC class I expression confers protection from macrophages in a murine tumor model (36). Here, LILRB1 is linked to neoplasm.